{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Response: Total"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Response: sCR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Response: CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Response: VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Response: PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Other Status: Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Other Status: Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Could not be assessed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Overall Response: Stringent Complete Response (sCR) + Complete Response (CR) + Very Good Partial Response (VGPR) + Partial Response (PR).","groups":[{"description":"Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"AZD6244 (Selumetinib) Treatment"}],"paramType":"NUMBER","populationDescription":"All participants who received study treatment","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"participants"}